Regulatory subunit type I‐α of protein kinase A (PRKAR1A): A tumor‐suppressor gene for sporadic thyroid cancer

The tumor‐suppressor gene encoding the cyclic AMP‐dependent protein kinase A type I‐α regulatory subunit PRKAR1A has been mapped to chromosome 17 (17q22–24) and is mutated in Carney complex, a familial neoplasia syndrome that is associated with thyroid tumors. Other genes implicated in cyclic nucleotide‐dependent signaling have been investigated in thyroid tumorigenesis. We studied protein kinase A (PKA) activity in noninherited follicular thyroid adenomas and follicular, papillary, and undifferentiated (anaplastic) thyroid carcinomas. We then examined these and additional thyroid tumors for losses of the 17q22–24 PRKAR1A region, mutations of the PRKAR1A gene, and expression of its peptide product. Total PKA activity was markedly increased in carcinomas over that in adenomas, whereas the ratio of free vs. total PKA activity was decreased in cancer. Consistent with these findings, the 17q22–24 region was frequently lost in cancer but not in benign adenomas. A novel inactivating mutation of the PRKAR1A gene (leading to premature termination of the predicted protein) was found in an aggressive thyroid cancer. The tumor with PRKAR1A gene mutation, as well as the tumors with 17q allelic losses, showed decreased PRKAR1A expression by immunostaining. We conclude that PRKAR1A, the most abundant regulatory subunit of protein kinase A and a principal cyclic AMP‐signaling modulator, acts as a tumor‐suppressor gene in sporadic thyroid cancer. Published 2002 Wiley‐Liss, Inc.

[1]  L. Thompson,et al.  Papillary Thyroid Carcinoma , 2004, Ear, nose, & throat journal.

[2]  K. Becker,et al.  Antisense DNAs as multisite genomic modulators identified by DNA microarray , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Daniel McCormick,et al.  Phosphorylation of Centrin during the Cell Cycle and Its Role in Centriole Separation Preceding Centrosome Duplication* , 2001, The Journal of Biological Chemistry.

[4]  P. Reynolds,et al.  Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. , 2001, The Journal of clinical endocrinology and metabolism.

[5]  C. Stratakis,et al.  Genetic heterogeneity and spectrum of mutations of the PRKAR1A gene in patients with the carney complex. , 2000, Human molecular genetics.

[6]  P. Crespo,et al.  Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation , 2000, Oncogene.

[7]  C. Stratakis,et al.  Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the "complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas" (Carney complex). , 2000, The Journal of clinical endocrinology and metabolism.

[8]  C. Eng,et al.  Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. , 2000, The American journal of pathology.

[9]  C. Stratakis,et al.  Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex , 2000, Nature Genetics.

[10]  C. Eng.  Familial papillary thyroid cancer--many syndromes, too many genes? , 2000, The Journal of clinical endocrinology and metabolism.

[11]  N. Sarlis.  Expression Patterns of Cellular Growth-Controlling Genes in Non-Medullary Thyroid Cancer: Basic Aspects , 2000, Reviews in Endocrine and Metabolic Disorders.

[12]  M. Emi,et al.  Allelotyping of anaplastic thyroid carcinoma: Frequent allelic losses on 1q, 9p, 11, 17, 19p, and 22q , 2000, Genes, chromosomes & cancer.

[13]  C. Stratakis,et al.  Genetics of Carney complex and related familial lentiginoses, and other multiple tumor syndromes. , 2000, Frontiers in bioscience : a journal and virtual library.

[14]  S. Filetti,et al.  The 3',5'-Cyclic Adenosine Monophosphate Response Element Binding Protein (CREB) Is Functionally Reduced in Human Toxic Thyroid Adenomas1. , 2000, Endocrinology.

[15]  S. Bates,et al.  Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristate-lacking Calpha and RIIbeta subunit overexpression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Harris Pe,et al.  Mutation analysis of protein kinase A catalytic subunit in thyroid adenomas and pituitary tumours. , 1999 .

[17]  M. O’Donovan,et al.  Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. , 1999, Clinical chemistry.

[18]  Kirschner Ls,et al.  Large-scale preparation of sequence-ready bacterial artificial chromosome DNA using QIAGEN columns. , 1999 .

[19]  F. Bosman,et al.  The hamartoma–adenoma–carcinoma sequence , 1999, The Journal of pathology.

[20]  J. Fagin,et al.  Genetic and epigenetic alterations of the cyclin‐dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas , 1998, Cancer.

[21]  J. Carney,et al.  Carney complex: diagnosis and management of the complex of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas. , 1998, American journal of medical genetics.

[22]  J. Jen,et al.  Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors , 1998, Genes, chromosomes & cancer.

[23]  M. O’Donovan,et al.  Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection. , 1998, Genomics.

[24]  E. Milgrom,et al.  Oncogenic potential of a mutant human thyrotropin receptor expressed in FRTL-5 cells , 1998, Oncogene.

[25]  M. Medvedovic,et al.  Studies of allelic loss in thyroid tumors reveal major differences in chromosomal instability between papillary and follicular carcinomas. , 1998, The Journal of clinical endocrinology and metabolism.

[26]  R. Paschke,et al.  Somatic Mutations in the Thyrotropin Receptor Gene and Not in the Gsα Protein Gene in 31 Toxic Thyroid Nodules1 , 1997 .

[27]  T. Shawker,et al.  Thyroid gland abnormalities in patients with the syndrome of spotty skin pigmentation, myxomas, endocrine overactivity, and schwannomas (Carney complex) , 1997, The Journal of clinical endocrinology and metabolism.

[28]  J. Fagin.  Familial nonmedullary thyroid carcinoma--the case for genetic susceptibility. , 1997, The Journal of clinical endocrinology and metabolism.

[29]  C. Esapa,et al.  G protein and thyrotropin receptor mutations in thyroid neoplasia. , 1997, The Journal of clinical endocrinology and metabolism.

[30]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[31]  M. Parmentier,et al.  Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene. , 1996, Oncogene.

[32]  C. Tsigos,et al.  Cytogenetic and microsatellite alterations in tumors from patients with the syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity (Carney complex). , 1996, The Journal of clinical endocrinology and metabolism.

[33]  D. Papanicolaou,et al.  Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. , 1996, The Journal of clinical investigation.

[34]  M. Zou,et al.  Genetics of follicular thyroid cancer. , 1995, Endocrinology and metabolism clinics of North America.

[35]  K. Ain.  Papillary thyroid carcinoma : etiology, assessment and therapy , 1995 .

[36]  S. Filetti,et al.  Activating mutations of the TSH receptor in differentiated thyroid carcinomas. , 1995, Oncogene.

[37]  R. Radin,et al.  Carney complex: report of three cases. , 1995, Radiology.

[38]  S. Taylor,et al.  A refractory phase in cyclic AMP-responsive transcription requires down regulation of protein kinase A , 1995, Molecular and cellular biology.

[39]  S. Asa,et al.  Expression of growth factors and growth factor receptors in normal and tumorous human thyroid tissues. , 1995, Thyroid : official journal of the American Thyroid Association.

[40]  C. Tseng,et al.  Different growth control of the two human thyroid cell lines of adenomatous goiter and papillary carcinoma. , 1995, Thyroid : official journal of the American Thyroid Association.

[41]  M. Borrello,et al.  A t( 10; 17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma , 1994, Genes, chromosomes & cancer.

[42]  J. Parma,et al.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas , 1993, Nature.

[43]  E. Mazzaferri,et al.  Management of a solitary thyroid nodule. , 1993, The New England journal of medicine.

[44]  C. Carcano,et al.  Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A , 1993, Molecular and cellular biology.

[45]  M. Borrello,et al.  Identification of the product of two oncogenic rearranged forms of the RET proto-oncogene in papillary thyroid carcinomas. , 1992, Oncogene.

[46]  M. Santoro,et al.  PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.

[47]  G. Seitz,et al.  Multiple Cutaneous Myxomas Coinciding with Repeated Cardiac Myxomas. A Syndrome , 1989, The Thoracic and cardiovascular surgeon.

[48]  J. Jauniaux,et al.  The cyclic AMP-mediated stimulation of cell proliferation. , 1989, Trends in biochemical sciences.

[49]  J. Dumont,et al.  Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro. , 1988, The Journal of clinical endocrinology and metabolism.

[50]  M. Pike,et al.  AETIOLOGY OF MULTIPLE SCLEROSIS , 1981, The Lancet.

[51]  P. Greengard,et al.  Cyclic nucleotide-dependent protein kinases. V. Preparation and properties of adenosine 3',5'-monophosphate-dependent protein kinase from various bovine tissues. , 1970, Biochimica et biophysica acta.

[52]  A. Knudson,et al.  Chasing the cancer demon. , 2000, Annual review of genetics.

[53]  S. Filetti,et al.  The 3',5'-cyclic adenosine monophosphate response element binding protein (CREB) is functionally reduced in human toxic thyroid adenomas. , 2000, Endocrinology.

[54]  C. Esapa,et al.  Mutation analysis of protein kinase A catalytic subunit in thyroid adenomas and pituitary tumours. , 1999, European journal of endocrinology.

[55]  C. Stratakis,et al.  Large-scale preparation of sequence-ready bacterial artificial chromosome DNA using QIAGEN columns. , 1999, BioTechniques.

[56]  R. Paschke,et al.  Somatic mutations in the thyrotropin receptor gene and not in the Gs alpha protein gene in 31 toxic thyroid nodules. , 1997, The Journal of clinical endocrinology and metabolism.

[57]  M. Parmentier,et al.  Costimulation of adenylyl cyclase and phospholipase C by a mutant alpha 1B-adrenergic receptor transgene promotes malignant transformation of thyroid follicular cells. , 1997, Endocrinology.

[58]  W. Young,et al.  Primary pigmented nodular adrenocortical disease and its associated conditions , 1992 .

[59]  J. Dumont,et al.  Activation of the cyclic AMP cascade as an oncogenic mechanism: the thyroid example. , 1991, Biochimie.

[60]  J. Scott.  Cyclic nucleotide-dependent protein kinases. , 1991, Pharmacology & therapeutics.

[61]  C. Stratakis,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Ovarian Lesions in Carney Complex: Clinical Genetics and Possible Predisposition to Malignancy , 2022 .